Sorting nexin-1 is a candidate tumor suppressor and potential prognostic marker in gastric cancer

Xiao-Yong Zhan1,2,3, Yaqiong Zhang2,3, Ertao Zhai1, Qing-Yi Zhu2,3 and Yulong He1

1 The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
2 Guangzhou KingMed Center for Clinical Laboratory, Guangzhou, China
3 KingMed School of Laboratory Medicine, Guangzhou Medical University, Guangzhou, China

ABSTRACT

Sorting nexin-1 (SNX1) is an important functional protein in cell endocytosis, efflux, protein sorting, cell signal transduction, etc; however, the expression, the role and clinical relevance of SNX1 have not been investigated in gastric cancer (GC). In this study, we first performed a bioinformatics investigation using the data obtained from The Cancer Genome Atlas (TCGA) database. The result showed that SNX1 mRNA levels were significantly lower in GC tissues than in paracancerous tissues. In a study of 150 cases of GC, including 60 cases with paired paracancerous and cancer tissues and 90 cases with detailed follow-up information, SNX1 expression was analyzed by immunohistochemistry. Our study on paired paracancerous and cancer tissues showed that SNX1 protein expression remarkably decreased in GC tissues (50/60, 83.33%). A study on 90 patients with detailed follow-up information showed that tumors with higher SNX1 protein level were correlated with better clinicopathologic stages ($p = 0.0285$), nodal status ($p = 0.0286$), smaller tumor sizes ($p = 0.0294$) and a better survival rate in patients with GC ($p = 0.0245$). Univariate analysis of the 90 patients with GC showed that low-level SNX1 protein level were correlated with better clinicopathologic stages ($p = 0.0285$), nodal status ($p = 0.0286$), smaller tumor sizes ($p = 0.0294$) and a better survival rate in patients with GC ($p = 0.0245$). Univariate analysis of the 90 patients with GC showed that low-level SNX1 was significantly correlated with decreased overall survival of GC patients ($p = 0.008$), and associated with a relatively higher cumulative hazard of death. Exogenous expression of SNX1 inhibited the growth, migration, invasion and promoted the apoptosis and enhanced the sensitivity of GC cells to the chemotherapeutic drug 5-Fluorouracil (5-Fu) in vitro, while knockdown of SNX1 by short hairpin RNA (shRNA) significantly promoted the growth, migration, invasion and reduced the apoptosis and the sensitivity of GC cells to 5-Fu. SNX1 also showed to influence the levels of epithelial-mesenchymal transition markers including Vimentin, Snail, and E-cadherin in GC cells in vitro. Taken together, we propose here that SNX1 serves as a tumor suppressor and prognostic marker that reduces tumor cell malignancy for GC.

INTRODUCTION

Gastric cancer (GC) is the fifth most common malignancy worldwide and causes the third most cancer-related death (Ferlay et al., 2015). There are many deaths caused by
GC in China every year which account for nearly half of the world’s GC deaths (Sheets, 2014). Several risk factors have been identified for GC, including Helicobacter pylori infection, Epstein-Barr virus infection, and dietary factors (Carrasco & Corvalan, 2013; Chen et al., 2015; Guggenheim & Shah, 2013). Mounting evidence showed that genetic factors, abnormal signal transduction and their downstream effects on cellular processes played important roles in GC (Gigek et al., 2017; McLean & El-Omar, 2014; Razzak, 2014). The pathogenesis of GC is still quite complex although numerous studies investigated molecular mechanisms of the initiation and development of GC. Therefore, investigating the pathogenesis of GC, finding new biomarkers with higher sensitivity and representability are desired.

Sorting nexin-1 (SNX1), the first member of the sorting nexins (SNXs) found in mammals, was discovered in 1996 by a yeast two-hybrid experiment, in which SNX1 could interact with epidermal growth factor receptor (EGFR) and accelerated its degradation (Kurten, Cadena & Gill, 1996). Further works demonstrated that SNX1 played an important role in cell endocytosis, efflux, protein sorting, cell signal transduction, membrane transport and remodeling, and organelle movement (Bryant et al., 2007; Gokool, Tattersall & Seaman, 2007; Nishimura et al., 2011; Zhang et al., 2013). SNX1 is associated with many intracellular signaling pathways. Downregulation of SNX1 promotes HGF-induced MET (product of oncogene c-met) endocytosis and leads to the phosphorylation of MET in human lung cancer cell line, and then activates RTK/RAS signaling pathway and leads to the activation of cell proliferation and inhibition of cell apoptosis, and increase cell malignancy (Nishimura et al., 2015; Peschard & Park, 2007; Stuart et al., 2000). SNX1 is also reported to suppress EGFR membrane recycling and activate EGFR/PI3K/AKT signaling pathway in lung cancer cells (Nishimura et al., 2015). Besides above, SNX1 is associated with some other pathologies including bacterial infection and hypertension. SNX1 defines an early phase of Salmonella-containing vacuole-remodeling during Salmonella infection thus it could regulate intracellular bacterial progression and replication (Bujny et al., 2008). SNX1 is required for dopamine D5 receptor function in human renal proximal tubule cells (Villar et al., 2010), and its loss results in D5 dopamine receptor dysfunction in human renal proximal tubule cells, thus it may be associated with hypertension (Villar et al., 2013). SNX1 is also reported to have an association with the development and metastasis of some tumors, including lung cancer and colon cancer (Bian et al., 2016; Chen et al., 2014; Holdren, Her & Parks, 2005; Nguyen et al., 2006; Nishimura et al., 2012). Despite these findings, the expression of SNX1 in other tumor tissues and the role of SNX1 in the development and metastasis of other tumor tissues remains unknown and its detailed clinical value remains to be elucidated. Thus, in this study, we investigated the SNX1 expression, the potential functional mechanism, and its prospect as a potential prognostic marker in GC.

MATERIALS AND METHODS

The Cancer Genome Atlas (TCGA) database analysis
To determine the potential role of SNX1 in GC, we performed a bioinformatics analysis using TCGA database (Tomczak, Czerwinska & Wiznerowicz, 2015) (https:
Stomach adenocarcinoma gene expression data were manually retrieved from the UCSC Cancer Genomics Browser (https://genome-cancer.ucsc.edu) and then extracted and checked. Data processing followed the instruction of the database and report elsewhere (Wang, Jensen & Zenklusen, 2016). SNX1 mRNA expression levels in 384 GC tissues and 37 non-cancerous paracancerous tissues (NCTs) were obtained and analyzed (Table S1).

**Tissue specimens and immunohistochemical staining**

Tumor specimens were obtained from 150 patients with primary GC and underwent a gastrectomy at the First Affiliated Hospital, Sun Yat-sen University from 2004 to 2016. Among them, sixty pairs of human GC tissues and adjacent NCTs were collected between 2009 and 2016. These tissues were used to research differential expression of SNX1 protein between tumor tissues and NCTs. Another 90 GC tissue samples were collected between 2004 to 2007. Detailed follow-up information was included in the patients with these tissues. Follow-up study was conducted up to December 31, 2013. They were used for the study of correlation of SNX1 with clinicopathologic characteristics and for the survival analysis and Cox Regression analysis. All human materials were obtained with informed consent, and this project was approved by the ICE for Clinical Research and Animal Trials of the First Affiliated Hospital, Sun Yat-sen University (approval ID 20172226). We retrieved the information, including gender, age, stage of disease and histopathological factors from the patient hospital charts. Patients’ data and clinical information are summarized in Table S2. The pathologic features of the specimens were classified based on the eighth edition of the tumor-node-metastasis (TNM) classification of the Union for International Cancer Control (UICC) and the American Joint Committee on Cancer (AJCC). Both tumor and adjacent NCTs were histologically examined. Tissue microarray construction was performed as described elsewhere (Fedor & De Marzo, 2005). The primary antibody was rabbit monoclonal antibody against SNX1 (1:100; Abcam). Quantifiable levels of SNX1 in the tissues were measured by histochemistry score (H-score), which was obtained based on the proportion and intensity of brown staining cells with calculation formula: H-score = (% of cells stained at intensity 1 × 1) + (% of cells stained at intensity 2 × 2) + (% of cells stained at intensity 3 × 3) (Yeo et al., 2015).

**Cell lines and culture**

Four human gastric cell lines, including a non-cancerous gastric epithelium cell line, GES-1 (Ke, Ning & Wang, 1994), and three GC cell lines, MKN-1, SGC-7901 and BGC-823, were purchased from the Type Culture Collection of the Chinese Academy of Sciences. All cells were maintained in RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS). Cells were grown under a 5% CO2 atmosphere at 37 °C.

**RNA extraction and quantitative real-time polymerase chain reaction (qRT-PCR) analysis**

Total RNA was extracted by Trizol (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s instructions. qRT-PCR was performed using TransScript Green One-Step qRT-PCR SurperMix (Transgene, Shenzen, China), in a total volume of
20 \mu l containing RNA, 2 \times SupperMix, and 0.2 \mu M of each primer. The primers used for qRT-PCR were: SNX1-F, 5′-GTGGTGCTGTTCTCTCAAG-3′; SNX1-R, 5′-CGGTGCCAGCTCACACT-3′. GAPDH-F, 5′-GCAACCTCAAGGCTGAGAA-3′; GAPDH-R, 5′-GTGAAGACGAGCCATGGACTC-3′.

**Vector construction and transfection**

For SNX1 exogenous expression vector construction, the SNX1 coding region was amplified from the cDNA of GES-1 cells by using the following primers:

5′-GCCACCATGGCCGTCGGGTGGTGGT-3′ and 5′-GGAGATGGCCCTTTGCTCACAGA-3′. The PCR product was then subcloned into the pEASY-Blunt M3 plasmid (Transgene, Beijing) to generate SNX1 overexpression plasmid (pEASY-SNX1). For SNX1 short hairpin RNA (shRNA) vector construction, the specific sequence used for the depletion of SNX1 (5′-CACGTAGCCTTCTCAGTTCTTAAGAGAACTGACACGTTCGAGAACTTTTTT-3′) was synthesized and then subcloned into the pGPU6-RFP-Neo plasmid (Genepharma, Shanghai, China) to generate SNX1 downregulation plasmid (shRNA-SNX1). The product of the small interfering RNA (siRNA) of this sequence was shown to have a knockdown level of 97% for SNX1 based on Sigma MISSION® shRNA. For control, pEASY-Blunt M3 empty plasmid (pEASY), and shRNA-control vector was constructed. The sequence (5′-CACGGTTCTCCAGGACGTCACGTTTCAAGAGAACGTACACGTTCAGAGAACTTTTT-3′) which generated an siRNA with no significant homology to any human gene sequences, was subcloned into the pGPU6-RFP-Neo plasmid (Genepharma, Shanghai, China) to generate shRNA-control plasmid (shRNA-control). For transient transfection assays, cells were transfected with each plasmid using Lipo6000 (Beyotime, Beijing, China), and were harvested after 48 h for further analysis.

**Western blotting (WB)**

Whole-cell lysates (20 \mu g total protein) were immunoblotted using antibodies against SNX1 and other antibodies. The primary antibodies used in this study are summarized in Table S3. Antigen-antibody complexes were visualized by Western blotting ECL Reagent (Beyotime, Beijing, China).

**Colony formation assay and scratch wound healing assay**

Transfected cells were trypsinized and counted. Five hundred cells were maintained for 15 days in RPMI1640 medium with 2% FBS, and cells were then fixed, stained and photographed.

Scratch wound healing assay was performed to determine the influence of SNX1 on cell migration. Briefly, transfected cells were counted with a cell counter (Bio-Rad). 2 \times 10^6 cells were inoculated in each well of 6-well plates for 24 h, and then a scratch wound was made by scraping the cell monolayer across the cover with a 10 \mu l sterile micro-pipette tips. The cells were then washed with PBS to eliminate residual floating cells. Wounded cultures were maintained in RPMI 1640 medium with 2% FBS and photographs were taken at 0 h, 12 h, 24 h, and 48 h. The migration distance of the cells was calculated by Image J (https://imagej.nih.gov/ij/).
Transwell cultures
Transwell cultures were performed as described elsewhere (Marshall, 2011). Briefly, the cultures were set up in 24-well plates. For invasion assay, $6 \times 10^4$ cells (in 300 µl RPMI1640 medium with 2% FBS) were seeded on the upper chamber of a 24-well Matrigel-coated membrane with 8 µm pores (Corning, Corning, NY, USA), and the bottom chamber was filled with RPMI1640 medium with 20% FBS. For the migration assay, $4 \times 10^4$ cells (in 200 µl RPMI1640 medium with 2% FBS) cells were directly seeded on an uncoated chamber. After 48 h of culture, the membranes were fixed and then stained with 0.1% methylrosaniline chloride solution, and invasion and migration were quantified by counting five random fields under a microscope (200×).

Cell proliferation and apoptosis assay
Cell proliferation was measured by a TransDetect Cell Count Kit (Transgene, Beijing, China) according to the manufacturer’s instructions. Briefly, 2,000 cells were inoculated in each well of a 96-well plate in RPMI 1,640 medium with 10% FBS. The CCK-8 solution was added to the wells at 24 h, 48 h, 72 h, 96 h, and 120 h, respectively. After two hours of incubation at 37 °C in a humidified incubator containing 5% CO2, OD450 values of these wells were obtained by using a microplate reader (SpectraMax i3; Molecular Devices, Shanghai, China). Cell apoptosis was determined by an Annexin V-FITC Apoptosis Detection Kit (Beyotime, Beijing, China), according to the manufacturer’s instruction. Because the cells transfected with shRNA-control or shRNA-SNX1 plasmid expressed red fluorescence protein, thus the propidium Iodide (PI) could not be used in the apoptosis detection. We gated the living cells (normal cells and apoptotic cells) on the basis of forward (FSC) and side (SSC) scatter characteristics, and then analysis the annexin V-FITC staining of these cells, as previously described (Zhan et al., 2014).

Statistical analysis
Relative mRNA level of SNX1 between NCTs and GC tissues were analyzed by t-test or paired t-test. The Mann–Whitney U test or Kolmogorov–Smirnov test was used to analyze different H-score between variables obtained from clinicopathological parameters. Spearman’s correlation analysis was used to analyze the relationship between survival months and SNX1 H-scores. Survival curves were estimated by the Kaplan–Meier method and compared by the log-rank test. Cox Regression analysis was used to analyze the hazard ration using univariate Cox proportional hazards model. Each in vitro assay has at least three replications and the t-test was used in comparisons of variables for in vitro assays. $p < 0.05$ was considered significant. GraphPad Prism 6 (GraphPad Software) was used for graphing. Statistical analyses were performed using SPSS 16.

RESULTS
Expression of SNX1 in GC
We found differential expression of SNX1 mRNA between GC tissues and NCTs through the TCGA database analysis: the GC tissues had a lower level of SNX1 mRNA (t-test and paired t-test, $p < 0.01$, Fig. S1). Then the protein expression of SNX1 was evaluated in
Figure 1  Staining for SNX1 protein expression in NCTs and GC tissues. (A–B) IHC staining of SNX1 in NCTs. (C–D) IHC staining of SNX1 in GC tissues. (E) Protein expression of SNX1 was decreased in 83.33% GC tissues by comparing the H-score of 60 paired GC tissues and adjacent NCTs. (F) Comparison between the H-scores of SNX1 in the NCTs and GC tissues. SNX1 protein expression is reduced in GC. Scale bar (A and C) 150 μm; (B and D) 50 μm.

60 paired GC tissues and NCTs by immunohistochemistry (IHC). As shown in Figs. 1A and 1B, SNX1 expression was exclusively in the cytoplasm of NCTs. In most cases, GC tissues presented weaker and less diffuse staining than NCTs (Figs. 1C and 1D). Overall, the protein level of SNX1 was downregulated in 83.33% (50/60) of GC tissues compared with NCTs (Fig. 1E). We defined a more than 50% of decrease or increase of the H-score
Table 1  SNX1 expression in human with gastric cancer.

| Clinicopathological parameters | Patients, n (%) | H-score (Median) | p values (Mann–Whitney U test) |
|-------------------------------|-----------------|------------------|---------------------------------|
| Age                           |                 |                  |                                 |
| <60                           | 59 (66)         | 14.58            | 0.264                           |
| ≥60                           | 31 (34)         | 16.56            |                                 |
| Gender                        |                 |                  |                                 |
| Male                          | 54 (60)         | 15.56            | 0.602                           |
| Female                        | 36 (40)         | 15.10            |                                 |
| Pathology-stages (pTNM)       |                 |                  |                                 |
| I–II                          | 41 (46)         | 15.90            | 0.0285                          |
| III–IV                        | 49 (54)         | 13.81            |                                 |
| Histological grades           |                 |                  |                                 |
| 2                             | 22 (24)         | 14.39            | 0.902                           |
| 3                             | 68 (76)         | 15.72            |                                 |
| Lymph node metastasis         |                 |                  |                                 |
| N0+N1                         | 50 (56)         | 16.58            | 0.0286                          |
| N1+N2                         | 40 (44)         | 13.00            |                                 |
| Invasive depth                |                 |                  |                                 |
| T1+T2                         | 16 (18)         | 16.23            | 0.989                           |
| T3+T4                         | 73 (82)         | 14.60            |                                 |
| Tumor size                    |                 |                  |                                 |
| Small                         | 55 (61)         | 20.03            | 0.0294                          |
| Big                           | 35 (39)         | 12.83            |                                 |

Notes.

* Tumor diameter ≤5 centimeters was defined small and >5 centimeters was defined big.

* p value <0.05 was considered significant.

& Kolmogorov–Smirnov test was used to compare the levels of SNX1 between different pTNM groups, and the p value was 0.0645 through Mann–Whitney U test.

in the GC tissues compared with the paired-NCTs as underexpression or overexpression. A significant reduction of SNX1 expression was observed in the GC tissues (p < 0.0001, Fig. 1F). Specifically, GC tissues displayed an extremely low level of SNX1 compared with NCTs that the median H-score was 1.82 in GC tissues and 34.81 in NCTs.

Correlation between SNX1 expression and clinicopathological parameters

To investigate the clinicopathological significance of SNX1 expression in GC, the potential associations between SNX1 expression and patients’ clinicopathological features were analyzed. Noticeably, the reduction of SNX1 protein in GC tissues was significantly associated with bigger tumor size (p = 0.0294), poor nodal status (p = 0.0286), and poor tumor p-stage (p = 0.0285) (Table 1). However, SNX1 expression was not associated with age, gender, histological grades and invasive depth (p > 0.05).

Association of SNX1 expression with the survival rate of GC patients

SNX1 protein levels were positively correlated with overall survival months of the patients (Fig. 2A). A higher survival rate was observed in patients with high-level SNX1, and the
Figure 2. SNX1 expression is related to poor prognosis of GC patients. (A) The protein level of SNX1 was positively correlated with survival time in the 90 patients. (B) Kaplan-Meier survival curve and log-rank test were used to evaluate the overall survival based on the protein levels of SNX1. (C) Survival curve based on the Cox Regression analysis. High-level SNX1 was defined as H-score > 15, while low-level SNX1 was defined as H-score < 15 and the 90 patients were divided into high-level and low-level groups (each group had 45 patients). (D) Cumulative hazard of death associated with low-level SNX1 or high-level SNX1.

5-year survival rate in patients with high-level SNX1 was much higher than those with low-level SNX1 (35.56% for the patients with high-level SNX1 and 13.33% for the patients with low-level SNX1; Fig. 2B). Collectively, these results suggest that the downregulation of SNX1 is involved in the development, progression, and prognosis of GC and SNX1 may be a potential prognostic marker of GC. Univariate analysis also showed that the low-level SNX1 was correlated with decreased overall survival of GC patients (Table 2). We brought the clinicopathological features that thought may be associated with survival including the pathology-stages, nodal status, and tumor histological grades into the multivariate analysis. Low-level SNX1 was also shown to be an independent risk factor for survival. Patients with low-level SNX1 have a high risk of death (hazard ration = 1.708, 95% CI [1.060–2.751], p = 0.028). The survival curve based on Cox Regression analysis was similar to that based on Kaplan-Meier method (Fig. 2C), and the patients with low-level SNX1 also had a higher cumulative hazard of death than those with high-level SNX1 (Fig. 2D).
Table 2  Univariate Cox’s analysis of overall survival for the 90 patients with GC.

| Parameters                                    | p values | Hazard ratio | 95% CI    |
|-----------------------------------------------|----------|--------------|-----------|
| Age (<60/≥60)                                 | 0.402    | 1.237        | 0.752–2.037|
| Gender (male/female)                          | 0.122    | 0.672        | 0.406–1.113|
| pTNM (I–II/III–IV)                            | 0.982    | 1.009        | 0.459–2.221|
| Histological grades (2/3)                     | 0.257    | 0.715        | 0.400–1.277|
| Lymph node metastasis (N0-N1/N2-N3)           | 0.273    | 0.670        | 0.327–1.372|
| Invasive depth (T1+T2/T3+T4)                  | 0.841    | 0.926        | 0.438–1.958|
| Tumor size (≤5/>5 centimeters)                | 0.790    | 0.932        | 0.554–1.568|
| SNX1 level (low/high)                         | **0.008**| 2.141        | 1.220–3.759|

**Effects of SNX1 on GC cell behavior in vitro**

To further investigate the role of SNX1 in the GC cells, first, we performed qRT-PCR assays to quantify SNX1 expression in four cell lines. As shown in Fig. 3A, qRT-PCR results revealed that GC cell lines including MKN-1, SGC-7901 and BGC-823 expressed relative lower mRNA level of SNX1 compared with the normal human gastric mucosal epithelium GES-1 cell line. WB results also showed that SNX1 was weakly detected in the GC cell lines (Fig. 3B).

For a functional investigation of SNX1, the GC cell lines with a moderate level of SNX1 (MKN-1 and SGC-7901) were selected for exogenous SNX1 expression or knockdown of SNX1 by shRNA and further analysis. We monitored the effect of SNX1 on the capacity of GC cell colony formation, cell migration and invasion, cell proliferation, cell apoptosis and cell sensitivity to traditional chemotherapeutic drugs 5-Fluorouracil (5-Fu) and oxaliplatin.

As shown in Fig. 52, the transfection of pEASY-SNX1 or shRNA-SNX1 could upregulate or downregulate SNX1 expression. Overexpression of SNX1 inhibited colony formation of GC cells, while knockdown of SNX1 enhanced the colony formation ability (Figs. 4A–4C). To determine whether SNX1 may play a role in cell migration, we performed a scratch wound healing assay and a transwell migration assay. Our results showed that
Figure 4  SNX1 inhibits the colony formation, the migration and invasion of GC cell in vitro.  (A) Representative photographs of colony formation of GC cells.  (B–C) Overexpression of SNX1 in GC cells led to the inhibition of the ability of colony formation (continued on next page...)

Full-size DOI: 10.7717/peerj.4829/fig-4
overexpression of SNX1 inhibited the migration ability, while knockdown of SNX1 enhanced the migration ability (Figs. 4D–4I). Matrigel invasion assay showed that overexpression of SNX1 inhibited the invasion ability while knockdown of SNX1 enhanced the invasion ability of GC cells (Figs. 4J–4L). These results suggested that SNX1 inhibits the invasion and metastasis abilities of GC cells.

Cell proliferation assay revealed that overexpression of SNX1 inhibited cell proliferation, while knockdown of SNX1 promoted cell proliferation (Fig. 5). A flow cytometry assay was used to detect cell apoptosis. Because annexin V-FITC+/annexin V-FITC- cell grouping was not obvious, we determined the apoptotic levels of cells by measuring both apoptotic rates (percentage of annexin V-FITC+ cells) and mean apoptotic fluorescence intensity (MFI, mean fluorescence intensity of FITC). It generally showed that cell apoptotic rates and MFI were both lower in GC cells with downregulated SNX1 and higher in GC cells with overexpressed SNX1, indicating that overexpression of SNX1 promoted cell apoptosis although sometimes not significantly (for MKN-1 cells), while knockdown of SNX1 significantly inhibited cell apoptosis (Fig. 6). We also found that overexpression of SNX1 in MKN-1 cells may not always lead to significantly high-level of apoptosis when compared with control. This may be because of the relative higher background expression level of SNX1 in this cell line (Fig. 3), which might lead to the low sensitivity of MKN-1 cells to overexpression of SNX1. Furthermore, we assessed the effect of SNX1 on the response of GC cells to chemotherapy drug 5-Fu and oxaliplatin. As shown in Figs. 7A and 7B,
Figure 6  Flow cytometry assays to detect apoptotic levels of GC cells treated with 5-Fu or oxaliplatin. (A) Living cells (normal cells and apoptotic cells) gated on the basis of FSC and SSC scatter characteristics. (B–D) The figures present the difference in the apoptotic levels in the different GC cells (transfected with different vectors) treated without or with 5-Fu/oxaliplatin. The (continued on next page...)

Full-size DOI: 10.7717/peerj.4829/fig-6
overexpression of SNX1 reduced the survival of cells treated with 5-Fu relative to untreated cells, while knockdown of SNX1 enhanced the cell survival. However, we didn’t find SNX1 upregulated chemo-sensitivity of GC cells to oxaliplatin although SNX1 could enhance apoptosis when cells were treated with oxaliplatin (Figs. 6D–6H, 7C and 7D). These results together indicated that SNX1 functioned as a tumor suppressor in GC and increased chemo-sensitivity of GC cells to 5-Fu.

Effects of SNX1 on epithelial-mesenchymal transition (EMT) of GC cells

We found in the 90 patient with GC that SNX1 was associated with lymph node metastasis ($p = 0.0286$, Table 1). We also found that SNX1 inhibited the migration and invasion abilities of GC cells in vitro (Figs. 4D–4L). Thus, we postulated that SNX1 may affect the EMT of GC cells. To test this hypothesis, we investigated the expression of molecular markers epithelial-mesenchymal transition in the cells using WB. Our study suggested that overexpression of SNX1 in GC cells led to downregulation of Vimentin and Snail; and upregulation of E-cadherin (Fig. 8). This might lead to the inhibition of migration and invasion of these cells.

DISCUSSION

GC remains to be one of the most threatening malignant tumors worldwide. It is a solid tumor with complex genetic and environmental interactions that contribute to its initiation and progression (McLean & El-Omar, 2014). Uncovering the etiology of GC is important for its prevention and treatment, but more detailed mechanisms of the development and progression of GC are still required to research.

As an important member of sorting nexin family, the expression and the potential role of SNX1 in malignancies have rarely been documented yet. The TCGA database favored our research and showed differential expression of SNX1 mRNA in NCTs and GC tissues (Fig. S1). This result led us to further investigate SNX1 protein levels in NCTs and GC tissues. Our histology research strongly suggests that downregulation of SNX1 is a significant factor in the development of human GC. We found that 83.33%
Figure 7  SNX1 increases the sensitivity of GC cells to 5-Fu but not to oxaliplatin. (A–B) Knockdown of SNX1 significantly reduced the sensitivity of GC cells to 5-Fu. (C–D) SNX1 did not increase the sensitivity of GC cells to oxaliplatin. The cell vitality was measured by CCK-8 assay. *p < 0.05; **p < 0.01; ***p < 0.001.

Figure 8  SNX1 regulates the expression of EMT markers. Overexpression of SNX1 leads to the down-regulation of Snail and Vimentin and upregulation of E-cadherin in (A) SGC-9701 cells and (B) MKN-1 cells.
(55/60) of the tumor tissues showed immunohistochemical evidence of significant SNX1 reduction (Fig. 1). In addition, study on the 90 patients with detailed follow-up data showed that downregulation of SNX1 in GC was significantly associated with bigger tumor size ($p = 0.0294$), poor tumor stage ($p = 0.0285$) and poor nodal status ($p = 0.0286$) (Table 1), and SNX1 might act as a potential prognostic marker of GC based on the survival curve analysis (Fig. 2). Cox Regression analysis showed that low-level SNX1 was correlated with decreased overall survival of GC patients, and it was an independent risk factor for survival (Table 2). We also found multiple alterations in human GC cells when depletion of this protein or overexpression of this protein (Figs. 4–8). Knockdown of SNX1 resulted in more colony formation, higher cell migration and invasion abilities (Fig. 4). In addition, downregulation of SNX1 increased proliferation, decreased apoptosis (Figs. 5 and 6). These changes in vivo synergize to increase tumor growth and may promote the ability of these tumor cells to metastasize. Downregulation of SNX1 was first reported in human colon cancer (Holdren, Her & Parks, 2005). After that, Nguyen et al. (2006) reported that SNX1 downregulation promoted colon tumorigenesis; increased EGFR phosphorylation and ERK 1/2 signaling. We estimated that the same signaling pathway might also happen in GC cells, and thus increased proliferation with decreased apoptosis following downregulation of SNX1 (Deschenes-Simard et al., 2014). Downregulation of SNX1 by microRNA-95 was reported to induce proliferation in non-small cell lung cancer (Chen et al., 2014). Based on these previous investigations and our present study, we hypothesize that SNX1 may act as an inhibitor of cell proliferation in many tumor cells.

Chemotherapy is an important care for gastric cancer (Fujitani et al., 2016). 5-Fu and oxaliplatin are two of the most effective anticancer regimens in the chemotherapy against numerous solid tumors (Graham, Mushin & Kirkpatrick, 2004; Longley, Harkin & Johnston, 2003). They are also the two common regimens for the treatment of patients with gastric cancer (Inadomi et al., 2017; Li et al., 2010). In this study, we found that knockdown of SNX1 promoted cell proliferation, inhibited cell apoptosis in 5-Fu and oxaliplatin treated cells (Fig. 6), and significantly enhanced the cell survival in 5-Fu treated cells which meant inhibition of chemo-sensitivity of cells to 5-Fu (Figs. 7A and 7B). SNX1 were shown to induce chemoresistance in non-small cell lung cancer (Chen et al., 2014). Bian et al. found histologic evidence that SNX1 expression is downregulated in human colorectal cancer and reported that overexpression of SNX1 enhanced chemo-sensitivity of colorectal cancer cells to both 5-Fu and oxaliplatin (Bian et al., 2016). However, we only found in the GC cells that overexpression of SNX1 enhanced chemo-sensitivity of GC cells to 5-Fu, but not to oxaliplatin. This might be related to different anti-tumor mechanism between the oxaliplatin and 5-Fu and different cell types (Eriguchi et al., 2003; Inada et al., 1997).

As an important protein family, SNXs have 33 members (SNX1 to SNX33). Many of which are involved in intracellular signaling pathway such as Wnt, EGFR, TGF-β, Notch etc. (Cullen & Korswagen, 2011; Kurten, Cadena & Gill, 1996; Parks et al., 2001). All of these pathways were reported to be associated with EMT in cancer cells (Holz et al., 2011; Yang et al., 2017; Zhang, Tian & Xing, 2016; Zhang et al., 2017). Thus, SNXs may regulate EMT. SNX27 was recently found to be associated with EMT in breast cancer cells (Li et al., 2015).
Our study also indicated that SNX1 was associated with EMT in gastric cancer cells as it showed that overexpression of SNX1 in GC cells inhibited migration and invasion, and led to upregulation of E-cadherin and downregulation of Vimentin and Snail (Fig. 8). David et al. have reported that SNX1 is required for efficient recycling of internalized E-cadherin and re-establishment of epithelial adhesion (Bryant et al., 2007). This may be a potential explanation for SNX1 to regulate EMT, but the exact mechanism needs to be further investigated. EMT played important roles in GC initiation and progression (Katoh, 2005; Peng et al., 2014). The markers of EMT (Vimentin, Snail, and E-Cadherin) were also shown to have special clinical significances to GC. Expression of Vimentin was reported to be associated with decreased survival in GC (Otsuki et al., 2011). Overexpression of Snail was shown to be associated with lymph node metastasis and poor prognosis in patients with GC (Ri et al., 2012). It was also shown to be an independent prognostic predictor for progression and patient survival of GC (He et al., 2012). In this study, we also found that low-level SNX1 was associated with lymph node metastasis, and patients with high-level SNX1 maintained a higher survival rate (Fig. 2, Table 1). These results suggested that SNX1 might regulate GC cell function in a variety of ways.

CONCLUSIONS

In summary, our histology research showed that SNX1 was downregulated in GC tissues and associated with a poor prognosis. This was the first histologic evidence showing SNX1 differential expression between GC and NCTs. We also demonstrated the clinicopathological significance of SNX1 protein expression in GC. Our cytology study on GC cells showed that SNX1 inhibited the colony formation, migration, invasion and proliferation of GC cells, and promoted the cell apoptosis and enhanced the sensitivity of GC cells to 5-Fu. Further study indicated that SNX1 might inhibit the EMT of GC cells. These results together suggested that SNX1 acted as a potential tumor suppressor and prognostic marker in GC, and might serve as a new therapeutic strategy for GC.

ADDITIONAL INFORMATION AND DECLARATIONS

Funding
This research was supported by the China Postdoctoral Science Foundation (grant number 2016M600701). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Grant Disclosures
The following grant information was disclosed by the authors:
China Postdoctoral Science Foundation: 2016M600701.

Competing Interests
The authors declare there are no competing interests.
Author Contributions

• Xiao-Yong Zhan conceived and designed the experiments, performed the experiments, analyzed the data, prepared figures and/or tables, authored or reviewed drafts of the paper, approved the final draft.
• Yaqiong Zhang performed the experiments, approved the final draft.
• Ertao Zhai performed the experiments, contributed reagents/materials/analysis tools, approved the final draft.
• Qing-Yi Zhu conceived and designed the experiments, approved the final draft.
• Yulong He conceived and designed the experiments, contributed reagents/materials/analysis tools, approved the final draft.

Human Ethics

The following information was supplied relating to ethical approvals (i.e., approving body and any reference numbers):

This project was approved by the ICE for Clinical Research and Animal Trials of the First Affiliated Hospital, Sun Yat-sen University (approval ID 2017226).

Data Availability

The following information was supplied regarding data availability:

The raw data were uploaded as Supplemental File.

Supplemental Information

Supplemental information for this article can be found online at http://dx.doi.org/10.7717/peerj.4829#supplemental-information.

REFERENCES

Bian Z, Feng Y, Xue Y, Hu Y, Wang Q, Zhou L, Liu Z, Zhang J, Yin Y, Gu B, Huang Z. 2016. Down-regulation of SNX1 predicts poor prognosis and contributes to drug resistance in colorectal cancer. Tumour Biology 37:6619–6625 DOI 10.1007/s13277-015-3814-3.

Bryant DM, Kerr MC, Hammond LA, Joseph SR, Mostov KE, Teasdale RD, Stow JL. 2007. EGF induces macropinocytosis and SNX1-modulated recycling of E-cadherin. Journal of Cell Science 120:1818–1828 DOI 10.1242/jcs.000653.

Bujny MV, Ewels PA, Humphrey S, Attar N, Jepson MA, Cullen PJ. 2008. Sorting nexin-1 defines an early phase of Salmonella-containing vacuole-remodeling during Salmonella infection. Journal of Cell Science 121:2027–2036 DOI 10.1242/jcs.018432.

Carrasco G, Corvalan AH. 2013. Helicobacter pylori-Induced chronic gastritis and assessing risks for gastric cancer. Gastroenterology Research and Practice 2013:Article 393015 DOI 10.1155/2013/393015.

Chen XZ, Chen H, Castro FA, Hu JK, Brenner H. 2015. Epstein-Barr virus infection and gastric cancer: a systematic review. Medicine 94:e792 DOI 10.1097/MD.0000000000000792.
Chen X, Chen S, Hang W, Huang H, Ma H. 2014. MiR-95 induces proliferation and chemoresistance through directly targeting sorting nexin1 (SNX1) in non-small cell lung cancer. *Biomedicine & Pharmacotherapy* **68**:589–595 DOI 10.1016/j.biopha.2014.04.008.

Cullen PJ, Korswagen HC. 2011. Sorting nexins provide diversity for retromer-dependent trafficking events. *Nature Cell Biology* **14**:29–37 DOI 10.1038/ncb2374.

Deschenes-Simard X, Kottakis F, Meloche S, Ferbeyre G. 2014. ERKs in cancer: friends or foes? *Cancer Research* **74**:412–419 DOI 10.1158/0008-5472.CAN-13-2381.

Eriguchi M, Nonaka Y, Yanagie H, Yoshizaki I, Takeda Y, Sekiguchi M. 2003. A molecular biological study of anti-tumor mechanisms of an anti-cancer agent Oxaliplatin against established human gastric cancer cell lines. *Biomedicine & Pharmacotherapy* **57**:412–415 DOI 10.1016/S0753-3322(03)00027-1.

Fedor HL, De Marzo AM. 2005. Practical methods for tissue microarray construction. *Methods in Molecular Medicine* **103**:89–101.

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebeco M, Parkin DM, Forman D, Bray F. 2015. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *International Journal of Cancer* **136**:E359–E386 DOI 10.1002/ijc.29210.

Fujitani K, Yang HK, Mizusawa J, Kim YW, Terashima M, Han SU, Iwasaki Y, Hyung WJ, Takagane A, Park DJ, Yoshikawa T, Hahn S, Nakamura K, Park CH, Kurokawa Y, Bang YJ, Park BJ, Sasaki M, Tsujinaka T, REGATTA study investigators. 2016. Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial. *The Lancet Oncology* **17**:309–318 DOI 10.1016/S1470-2045(15)00553-7.

Gigek CO, Calcagno DQ, Rasmussen LT, Santos LC, Leal MF, Wisneski F, Burbano RR, Loureno LG, Lopes-Filho GJ, Smith MAC. 2017. Genetic variants in gastric cancer: risks and clinical implications. *Experimental And Molecular Pathology* **103**:101–111 DOI 10.1016/j.yexmp.2017.07.004.

Gokool S, Tattersall D, Seaman MN. 2007. EHD1 interacts with retromer to stabilize SNX1 tubules and facilitate endosome-to-Golgi retrieval. *Traffic* **8**:1873–1886 DOI 10.1111/j.1600-0854.2007.00652.x.

Graham J, Mushin M, Kirkpatrick P. 2004. Oxaliplatin. *Nature Reviews Drug Discovery* **3**:11–12 DOI 10.1038/nrd1287.

Guggenheim DE, Shah MA. 2013. Gastric cancer epidemiology and risk factors. *Journal of Surgical Oncology* **107**:230–236 DOI 10.1002/jso.23262.

He H, Chen W, Wang X, Wang C, Liu F, Shen Z, Xu J, Gu J, Sun Y. 2012. Snail is an independent prognostic predictor for progression and patient survival of gastric cancer. *Cancer Science* **103**:1296–1303 DOI 10.1111/j.1349-7006.2012.02295.x.

Holden M, Her M, Parks WT. 2005. Sorting nexin 1 loss is an early event in colon cancer [Abstract 1342]. *Cancer Research* **65**.

Holz C, Niehr F, Boyko M, Hristozova T, Distel L, Budach V, Tinhofer I. 2011. Epithelial-mesenchymal-transition induced by EGFR activation interferes with cell
migration and response to irradiation and cetuximab in head and neck cancer cells. Radiotherapy And Oncology 101:158–164 DOI 10.1016/j.radonc.2011.05.042. Inada T, Ichikawa A, Kubota T, Ogata Y, Moossa AR, Hoffman RM. 1997. 5-FU-induced apoptosis correlates with efficacy against human gastric and colon cancer xenografts in nude mice. Anticancer Research 17:1965–1971. Inadomi K, Kusaba H, Matsushita Y, Tanaka R, Mitsugi K, Arimizu K, Hirano G, Makiyama A, Ohmura H, Uchino K, Hanamura F, Shibata Y, Kuwayama M, Esaki T, Takayoshi K, Arita S, Ariyama N, Akashi K, Baba E. 2017. Efficacy and safety analysis of oxaliplatin-based chemotherapy for advanced gastric cancer. Anticancer Research 37:2663–2671 DOI 10.21873/anticanres.11614. Villar VA, Jones JE, Armando I, Asico LD, Escano Jr CS, Lee H, Wang X, Yang Y, Pascua-Crusan AM, Pascua-Crusan CP, Felder RA, Jose PA. 2013. Sorting nexin 1 loss results in D5 dopamine receptor dysfunction in human renal proximal tubule cells and hypertension in mice. Journal of Biological Chemistry 288:152–163 DOI 10.1074/jbc.M112.428458. Katoh M. 2005. Epithelial-mesenchymal transition in gastric cancer (Review). International Journal of Oncology 27:1677–1683. Ke Y, Ning T, Wang B. 1994. Establishment and characterization of a SV40 transformed human fetal gastric epithelial cell line-GES-1. Zhonghua Zhong Liu Za Zhi 16:7–10. Kurten RC, Cadena DL, Gill GN. 1996. Enhanced degradation of EGF receptors by a sorting nexin, SNX1. Science 272:1008–1010 DOI 10.1126/science.272.5264.1008. Li K, Wu S, Playford M, Sun J. 2015. Deletion of sorting nexin 27 reverses epithelial-mesenchymal-transition in highly aggressive breast cancer cells [Abstract 926.20]. Faseb Journal 29. Li QF, Yao RY, Liu KW, Lv HY, Jiang T, Liang J. 2010. Genetic polymorphism of GSTP1: prediction of clinical outcome to oxaliplatin/5-FU-based chemotherapy in advanced gastric cancer. Journal of Korean Medical Science 25:846–852 DOI 10.3346/jkms.2010.25.6.846. Longley DB, Harkin DP, Johnston PG. 2003. 5-fluorouracil: mechanisms of action and clinical strategies. Nature Reviews Cancer 3:330–338 DOI 10.1038/nrc1074. Marshall J. 2011. Transwell((R)) invasion assays. Methods in Molecular Biology 769:97–110 DOI 10.1007/978-1-61779-207-6_8. McLean MH, El-Omar EM. 2014. Genetics of gastric cancer. Nat Rev Gastroenterol Hepatol 11:664–674 DOI 10.1038/nrgastro.2014.143. Nguyen LN, Holdren MS, Nguyen AP, Furuya MH, Bianchini M, Levy E, Mordoh J, Liu A, Guncay GD, Campbell JS, Parks WT. 2006. Sorting nexin 1 down-regulation promotes colon tumorigenesis. Clinical Cancer Research 12:6952–6959 DOI 10.1158/1078-0432.CCR-06-0317. Nishimura Y, Takiguchi S, Ito S, Itoh K. 2015. EGF-stimulated AKT activation is mediated by EGFR recycling via an early endocytic pathway in a gefitinib-resistant human lung cancer cell line. International Journal of Oncology 46:1721–1729 DOI 10.3892/ijo.2015.2871.
Nishimura Y, Takiguchi S, Yoshioka K, Nakabeppu Y, Itoh K. 2012. Silencing of SNX1 by siRNA stimulates the ligand-induced endocytosis of EGFR and increases EGFR phosphorylation in gefitinib-resistant human lung cancer cell lines. *International Journal of Oncology* 41:1520–1530 DOI 10.3892/ijo.2012.1578.

Nishimura Y, Yoshioka K, Takiguchi S, Bereczky B, Nakabeppu Y, Itoh K. 2011. A role for SNX1 in the regulation of EGF-dependent phosphorylated EGFR endocytosis via the early/late endocytic pathway in a gefitinib-sensitive human lung cancer cells. *Current Signal Transduction Therapy* 6:383–395 DOI 10.2174/157436211797484047.

Otsuki S, Inokuchi M, Enjoji M, Ishikawa T, Takagi Y, Kato K, Yamada H, Kojima K, Sugihara K. 2011. Vimentin expression is associated with decreased survival in gastric cancer. *Oncology Reports* 25:1235–1242 DOI 10.3892/or.2011.1185.

Parks WT, Frank DB, Huff C, Renfrew Haft C, Martin J, Meng X, De Caestecker MP, McNally JG, Reddi A, Taylor SI, Roberts AB, Wang T, Lechleider RJ. 2001. Sorting nexin 6, a novel SNX, interacts with the transforming growth-factor-beta family of receptor serine-threonine kinases. *Journal of Biological Chemistry* 276:19332–19339 DOI 10.1074/jbc.M100606200.

Peng Z, Wang CX, Fang EH, Wang GB, Tong Q. 2014. Role of epithelial-mesenchymal transition in gastric cancer initiation and progression. *World Journal of Gastroenterology* 20:5403–5410 DOI 10.3748/wjg.v20.i18.5403.

Peschard P, Park M. 2007. From Tpr-Met to Met, tumorigenesis and tubes. *Oncogene* 26:1276–1285 DOI 10.1038/sj.onc.1210201.

Razzak M. 2014. Genetics: new molecular classification of gastric adenocarcinoma proposed by The Cancer Genome Atlas. *Nature Reviews Clinical Oncology* 11:Article 499 DOI 10.1038/nrclinonc.2014.138.

Ri SN, Hui JE, In CC, Jung MH, Hwa KC, Sun CI, Ha KG, Yong JT, Hwan KD, Hyuk LJ. 2012. Overexpression of Snail is associated with lymph node metastasis and poor prognosis in patients with gastric cancer. *BMC Cancer* 12:521 DOI 10.1186/1471-2407-12-521.

Sheets F. 2014. All Cancers (excluding non-melanoma skin cancer) Estimated Incidence, Mortality and Prevalence Worldwide in 2012.

Stuart KA, Riordan SM, Lidder S, Crostella L, Williams R, Skouteris GG. 2000. Hepatocyte growth factor/scatter factor-induced intracellular signalling. *International Journal of Experimental Pathology* 81:17–30 DOI 10.1046/j.1365-2613.2000.00138.x.

Tomczak K, Czerwinska P, Wiznerowicz M. 2015. The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge. *Contemporary Oncology* 19:A68–77 DOI 10.5114/wo.2014.47136.

Villar VAM, Jones JE, Armando I, Asico LD, Escano CS, Wang X, Pascua AM, Li H, Palmes-Saloma CP, Jose PA. 2010. Sorting nexin 1 is crucial to dopamine D-5 receptor function in human renal proximal tubule cells. *Hypertension* 56:e123.

Wang Z, Jensen MA, Zenklusen JC. 2016. A practical guide to the cancer genome atlas (TCGA). *Methods in Molecular Biology* 1418:111–141 DOI 10.1007/978-1-4939-3578-9_6.
Yang Q, Cao X, Tao G, Zhou F, Zhao P, Shen Y, Chen X. 2017. Effects of FOXJ2 on TGF-β1-induced epithelial-mesenchymal transition through Notch signaling pathway in non-small lung cancer. *Cell Biology International* **41**:79–83 DOI 10.1002/cbin.10680.

Yeo W, Chan SL, Mo FK, Chu CM, Hui JW, Chan AW, Koh J, Hui EP, Loong H, Lee K, Li L, Ma B, To KF, Yu SC. 2015. Phase I/II study of temsirolimus for patients with unresectable Hepatocellular Carcinoma (HCC)- a correlative study to explore potential biomarkers for response. *BMC Cancer* **15**:395 DOI 10.1186/s12885-015-1334-6.

Zhan XY, Wang N, Liu G, Qin L, Xu W, Zhao S, Qin L, Chen X. 2014. Plasmodium infection reduces the volume of the viral reservoir in SIV-infected rhesus macaques receiving antiretroviral therapy. *Retrovirology* **11**:Article 112 DOI 10.1186/s12977-014-0112-x.

Zhang H, Zhou H, Berke L, Heck AJ, Mohammed S, Scheres B, Menke FL. 2013. Quantitative phosphoproteomics after auxin-stimulated lateral root induction identifies an SNX1 protein phosphorylation site required for growth. *Molecular & Cellular Proteomics* **12**:1158–1169 DOI 10.1074/mcp.M112.021220.

Zhang J, Tian XJ, Xing J. 2016. Signal transduction pathways of EMT induced by TGF-beta, SHH, and WNT and their crosstalks. *Journal of Clinical Medicine* **5**:Article 41 DOI 10.3390/jcm5040041.

Zhang L, Sha J, Yang G, Huang X, Bo J, Huang Y. 2017. Activation of Notch pathway is linked with epithelial-mesenchymal transition in prostate cancer cells. *Cell Cycle* **16**:999–1007 DOI 10.1080/15384101.2017.1312237.